Avadel Pharmaceuticals (AVDL) announced that Sev Melkonian has joined the company as Vice President of Patient Services, Distribution, and Reimbursement. Most recently, he led Patient Access Partner Operations at Takeda Pharmaceuticals (TAK), where he directed teams in support of Takeda’s USBU Portfolio including Rare Disease Patient Services Programs.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Pharmaceuticals price target lowered to $14 from $22 at UBS
- UBS cuts Avadel target, says shares ‘significantly cheap’
- Venu Sports JV discontinued, Walgreens reports Q1 beat: Morning Buzz
- Oppenheimer cuts Avadel target, would buy on weakness
- Avadel Pharmaceuticals price target lowered to $17 from $23 at Craig-Hallum